Alnylam Receives $10M from Takeda for Tech Transfer

The payment is related to a 2008 agreement under which Takeda received non-exclusive access to Alnylam's IP and technological expertise for RNAi drug development in cancer and metabolic disease.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.